Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Stage of Development | 9 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Therapy Area | 10 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Indication | 11 | 2 |
| Transforming Growth Factor Beta 1 (TGFB1) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Companies | 15 | 2 |
| Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Universities/Institutes | 17 | 2 |
| Transforming Growth Factor Beta 1 (TGFB1) Therapeutics Assessment | 19 | 6 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Transforming Growth Factor Beta 1 (TGFB1) Companies Involved in Therapeutics Development | 25 | 12 |
| Acceleron Pharma, Inc. | 25 | 1 |
| Digna Biotech, S.L. | 26 | 1 |
| Dong Wha Pharma Co., Ltd. | 27 | 1 |
| Eli Lilly and Company | 28 | 1 |
| Huabo Biopharm Co., Ltd. | 29 | 1 |
| Isarna Therapeutics GmbH | 30 | 1 |
| Johnson &Johnson | 31 | 1 |
| Novartis AG | 32 | 1 |
| Scholar Rock, Inc. | 33 | 1 |
| Sirnaomics, Inc. | 34 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 35 | 1 |
| TissueGene, Inc. | 36 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Drug Profiles | 37 | 23 |
| ACE-1332 Drug Profile | 37 | 1 |
| Antibody to Inhibit TGF-Beta 1 for Osteoarthritis Drug Profile | 38 | 1 |
| Antibody to Inhibit TGFB1 for Oncology Drug Profile | 39 | 1 |
| decorin Drug Profile | 40 | 1 |
| disitertide Drug Profile | 41 | 2 |
| DW-1029M Drug Profile | 43 | 1 |
| HB-001 Drug Profile | 44 | 1 |
| HB-002 Drug Profile | 45 | 1 |
| ISTH-1047 Drug Profile | 46 | 1 |
| ISTH-1106 Drug Profile | 47 | 1 |
| melittin Drug Profile | 48 | 1 |
| Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis Drug Profile | 49 | 1 |
| Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders Drug Profile | 50 | 1 |
| Monoclonal Antibody to Inhibit TGF Beta1 for Oncology Drug Profile | 51 | 1 |
| Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain Drug Profile | 52 | 1 |
| STP-705 Drug Profile | 53 | 2 |
| TASP-0382088 Drug Profile | 55 | 1 |
| tonogenchoncel-L Drug Profile | 56 | 3 |
| XOMA-089 Drug Profile | 59 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Dormant Projects | 60 | 3 |
| Transforming Growth Factor Beta 1 (TGFB1) Discontinued Products | 63 | 1 |
| Transforming Growth Factor Beta 1 (TGFB1) Featured News &Press Releases | 64 | 10 |
| Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer | 64 | 1 |
| Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGF 1 Latent Complex | 64 | 1 |
| May 11, 2015: TissueGene Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee | 65 | 1 |
| Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US | 65 | 2 |
| Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA | 67 | 1 |
| Nov 17, 2014: TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee | 68 | 1 |
| Nov 14, 2012: TissueGene Completes Enrollment In US Phase II Study Of TG-C In Patients With Knee Osteoarthritis | 68 | 1 |
| Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field | 68 | 2 |
| Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705 | 70 | 1 |
| May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee | 70 | 1 |
| Mar 25, 2010: Digna Biotech Announced The Results Of Disitertide Proof Of Concept Trial In The Topical Treatment Of Skin Fibrosis | 71 | 1 |
| Mar 03, 2009: TissueGene Announces Regulatory Allowance To Initiate Phase IIa Study Of TG-C In South Korea For Osteoarthritis Of The Knee | 71 | 1 |
| Oct 19, 2007: Digna Biotech Biotechnological Company and Isdin Laboratory Begin Phase II Of A Product For Scleroderma | 72 | 1 |
| Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial with TG-C | 72 | 1 |
| Apr 19, 2005: RheoGene Inc. And TissueGene Inc. Sign Collaborative Agreement For Bone Regeneration And Repair Program | 72 | 2 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |